Potential antitumour activity of pasireotide on pituitary tumours in acromegaly

Lancet Diabetes Endocrinol. 2019 Jun;7(6):425-426. doi: 10.1016/S2213-8587(19)30113-5. Epub 2019 Apr 4.

Authors

Eva C Coopmans¹, Aart J van der Lely², Joppe J Schneiders³, Sebastian J C M M Neggers²

Affiliations

¹ Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands. Electronic address: [email protected].
² Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.
³ Department of Radiology, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.

PMID: 30956093
DOI: 10.1016/S2213-8587(19)30113-5

No abstract available

Publication types

Letter

MeSH terms

Acromegaly / drug therapy*
Acromegaly / etiology
Adenoma / complications
Adenoma / diagnostic imaging
Adenoma / drug therapy*
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Growth Hormone-Secreting Pituitary Adenoma / complications
Growth Hormone-Secreting Pituitary Adenoma / diagnostic imaging
Growth Hormone-Secreting Pituitary Adenoma / drug therapy*
Hormones / therapeutic use*
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Somatostatin / analogs & derivatives*
Somatostatin / therapeutic use

Substances

Hormones
Somatostatin
pasireotide